Lymphoma News

An increasing number of oral anticancer drugs have been granted FDA approval and introduced into clinical practice.

NEW ORLEANS — The addition of subcutaneous epcoritamab to rituximab and lenalidomide demonstrated encouraging efficacy as first-line treatment for follicular lymphoma, according to results presented at ASH Annual Meeting and Exposition.

NEW ORLEANS — The addition of brentuximab vedotin and nivolumab to doxorubicin and dacarbazine appeared active among patients with advanced-stage classical Hodgkin lymphoma, according to study results.

NEW ORLEANS — Odronextamab showed promising efficacy among patients with grade 1 to grade 3a follicular lymphoma who received two or more prior lines of therapy, according to study results presented at ASH Annual Meeting and Exposition.

NEW ORLEANS — Zanubrutinib significantly prolonged PFS compared with ibrutinib among patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, results of the phase 3 ALPINE study showed.

NEW ORLEANS — A novel chimeric antigen receptor T-cell therapy conferred a 78% complete response rate in patients with heavily pretreated T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma, study results showed.

Spaceflight may place astronauts at increased risk for developing mutations that can lead to cancer and heart disease, according to a study published in Nature Communications Biology.

Michael A. Caligiuri, MD, and Christopher R. Flowers, MD, MS, will receive ASH Mentor Awards at this year’s ASH Annual Meeting and Exposition.

NEW ORLEANS — Patients with large B-cell lymphoma who achieved complete response at the end of glofitamab treatment had durable remissions and rarely experienced off-treatment progression within 1 year of therapy, according to study results.

NEW ORLEANS — Patients with newly diagnosed mantle cell lymphoma who received ibrutinib with a standard-of-care regimen had higher failure-free survival rates than those who received standard-of-care treatment alone.